International Stem Cell Corporation to Expand its Revenue Generating Biomedical Businesses to Support Clinical Trials
September 26 2017 - 08:30AM
InvestorsHub NewsWire
H1 2017 operating income from ISCO’s revenue
generating subsidiaries demonstrated an increase of 51% compared to
its income in H1 2016, while H1 2017 revenue was $3.8
million.
Edison Investment Research target price for ISCO shares
is $6.62 per share*
Carlsbad, CA -- September 26, 2017 -- InvestorsHub
NewsWire -- International Stem Cell Corporation (OTCQB:ISCO)
(www.internationalstemcell.com) ("ISCO" or "the Company"), a
California-based clinical stage biotechnology company that develops
novel stem cell-based therapies and biomedical products, announced
today that ISCO’s wholly owned subsidiaries Lifeline Cell
Technology (LCT) and Lifeline Skin Care (LSC) expanded their
manufacturing operations, OEM business, and product lines.
“ISCO was one of the first stem cell biotech companies to build a
business model in which revenue-generating subsidiaries operate
under a parent R&D company. This not only decreases cash burn
while conducting our Parkinson’s disease clinical trial, but gives
us more confidence in ISCO’s future” commented Russell Kern, PhD,
Executive VP and Chief Scientific Officer of ISCO.
Lifeline Cell Technology LLC, a research products business which
develops, manufactures, and commercializes human cell culture
products, expanded and improved its media manufacturing operation
by doubling the size of clean rooms, as well as the cell culture
media production capacity. LCT has expanded its catalog by
launching cardiac fibroblasts and skeletal muscle cell culture
system, which includes differentiation media. Also, while working
on bringing more international distributors, LCT expanded its
domestic sales force together with OEM business. In their catalog,
LCT currently has 60 different cell types and 115 media products,
which is comprised of 34 kits for growing the different cell types,
24 different cell culture media, and 57 growth
factors/cytokines.
Lifeline Skin Care Inc., a leader in stem cell skin care anti-aging
solutions, expanded its marketing operations and sales force, and
will be launching a new product in October 2017, Intense Moisture
Serum, a high-tech serum that combines advanced stem cell
technology with powerful concentrations of moisturizers. The
current consumer products line features 16 products, while the
professional line features 12.
“Backed by years of intensive research and development, Lifeline
Skin Care has developed a unique and advanced skin care line using
cutting-edge technologies that improves the skin's overall
appearance. It is definitely one of my top “Go To” to skin
care lines” commented Dr. Paul E. Chasan, MD, FACS.
LSC's products are distributed worldwide through its company
website (www.lifelineskincare.com) and domestically through a
network of dermatologists, plastic surgeons, and spas, including
The Woodhouse Day Spa®, a national luxury day spa franchise.
About International Stem Cell Corporation
International Stem Cell Corporation (ISCO) is focused on the
therapeutic applications of human parthenogenetic stem cells
(hpSCs) and the development and commercialization of cell-based
research and cosmetic products. ISCO's core technology,
parthenogenesis, results in the creation of human pluripotent stem
cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues
associated with the use or destruction of viable human embryos.
ISCO scientists have created the first parthenogenetic, homozygous
stem cell line that can be a source of therapeutic cells for
millions of individuals of differing genders, ages and racial
background with minimal immune rejection after transplantation.
hpSCs offer the potential to create the first true stem cell bank,
UniStemCell™. ISCO also produces and markets specialized cells and
growth media for therapeutic research worldwide through its
subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and
stem cell-based skin care products through its subsidiary Lifeline
Skin Care (www.lifelineskincare.com). More information is available
at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please
click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company
updates and industry related news, visit:
www.facebook.com/InternationalStemCellCorporation and
www.twitter.com/intlstemcell
Safe harbor statement
Statements pertaining to anticipated developments, expected results
clinical studies, progress of research and development initiatives,
growth expectations and other opportunities for the company and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects," "estimates,") should also be considered
to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation,
risks inherent in the development and/or commercialization of
potential products, regulatory approvals, need and ability to
obtain future capital, application of capital resources among
competing uses, and maintenance of intellectual property rights.
Actual results may differ materially from the results anticipated
in these forward-looking statements and as such should be evaluated
together with the many uncertainties that affect the company's
business, particularly those mentioned in the cautionary statements
found in the company's Securities and Exchange Commission filings.
The company disclaims any intent or obligation to update
forward-looking statements.
* The research report is available on Edison’s website http://www.edisoninvestmentresearch.com/research/company/international-stem-cell
Please note that ISCO has paid Edison Investment Research to
prepare the report.
International Stem Cell Corporation
Dr. Russell Kern
EVP, Chief Scientific Officer
(760)940-6383
ir@intlstemcell.com
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Feb 2024 to Mar 2024
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Mar 2023 to Mar 2024